Double Whammy For Hi-Tech’s Zostrix: FDA Warning, NAD Review
This article was originally published in The Tan Sheet
Executive Summary
Soon after Hi-Tech Pharmacal received an FDA warning letter about violative diabetes claims for its Zostrix pain relief topicals, the National Advertising Division released a case report recommending several Zostrix claims be modified or discontinued due to inadequate clinical support.
You may also be interested in...
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
Certain Dri Antiperspirant Sweats It Out Against Big Players
With a thicker, “drip-free” reformulation of Certain Dri launching in January 2014, DSE Healthcare Solutions hopes its clinical-strength roll-on antiperspirant will appeal to more consumers with hyperhidrosis as well as those concerned about but not diagnosed with excessive perspiration.